 |
|
|
| |
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5 or 6 Infection:
An Integrated Analysis of Phase 2 and 3 Studies
|
| |
| |
Reported by Jules Levin
EASL 2019 April 10-14 Vienna
Betty B Yao1, Tarik Asselah2, Linda Fredrick1, Gretja Schnell1, Kris Kowdley3, Paul Y Kwo4, Fred Poordad5, Kinh Nguyen6, Samuel S Lee7, Federico Mensa1
1AbbVie Inc., North Chicago, Illinois, United States; 2Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Université Paris Diderot, Department of Hepatology, AP-HP Hôpital Beaujon, Clichy, France; 3Swedish Medical Center, Seatt le, Washington, United States; 4Stanford University School of Medicine, Palo Alto, California, United States; 5The Texas Liver Institute, University of Texas Health, San Antonio, Texas, United States; 6National Hospital for Tropical Diseases, Vietnam; 7University of Calgary, Calgary, Alberta, Canada
|
| |
|
|
|
|
|
